Evaluating RZ-001 with Valganciclovir and Atezolizumab/Bevacizumab for Liver Cancer

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study evaluates the safety, tolerability, efficacy, and immunogenicity of RZ-001 in combination with Valganciclovir and Atezolizumab/Bevacizumab in patients with hepatocellular carcinoma (HCC) that is positive for human telomerase reverse transcriptase (hTERT). A total of 15 subjects will be enrolled in each of three cohorts, with dose escalation determined by the occurrence of dose-limiting toxicity after a review by a Safety and Efficacy Review Committee. The study aims to assess the potential benefits of this combination therapy in treating advanced liver cancer.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Adult males and females
* Hepatocellular carcinoma diagnosis (BCLC stage B or C)
* hTERT positive expression confirmed during the screening period
* ECOG score of 0 or 1
* Child-Pugh score of A
* Life expectancy \>= 3 months

Exclusion Criteria:

* Moderate or severe ascites
* History of hepatic encephalopathy
* Carcinomas other than HCC
* Current or history of HIV positive
* Not suitable for inclusion judged by the investigator

Where it's running

• Pusan National University Yangsan Hospital
  Busan, South Korea Recruiting
• Kyungpook National University Hospital
  Daegu, South Korea Recruiting
• Catholic University of Korea, Seoul St. Mary's Hospital
  Seoul, South Korea Recruiting
• Gangnam Severance Hospital
  Seoul, South Korea Recruiting
• Kangbuk Samsung Medical Center
  Seoul, South Korea Recruiting
• Korea University Guro Hospital
  Seoul, South Korea Recruiting

Study contacts

• Study coordinator: Rznomics, Inc.
• Email: rznomics@rznomics.com
• Phone: +82-31-706-8730

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Blood biomarkers to predict response to atezolizumab plus bevacizumab in hepatocellular carcinoma

  This study tests whether blood-based biomarkers can predict which patients with advanced liver cancer will respond to first-line atezolizumab plus bevacizumab.

  Recruiting Shanghai Zhongshan Hospital · Shanghai, Shanghai Municipality · NCT07734857

• TIPS benefits for people with hepatocellular carcinoma taking Tecentriq (atezolizumab) plus Avastin (bevacizumab) as first-line therapy.

  This study will try to see if placing a TIPS device helps people with advanced or unresectable hepatocellular carcinoma who are starting first-line treatment with Tecentriq plus Avastin.

  Recruiting Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest · Düsseldorf, North Rhine-Westphalia · NCT07365930

• FOLFOX chemotherapy with atezolizumab and bevacizumab after progression on atezolizumab plus bevacizumab for advanced liver cancer

  This trial will test whether giving FOLFOX chemotherapy together with continued atezolizumab and bevacizumab helps people with advanced hepatocellular carcinoma whose cancer progressed on prior atezolizumab plus bevacizumab.

  Recruiting Phase 2 Sun Yat-sen University · Guangzhou, Guangdong · NCT07192185

• Preventing esophageal varices in liver cancer patients treated with specific medications

  This study is testing whether treating liver cancer patients with specific medications can help prevent the worsening of esophageal varices and reduce the risk of bleeding.

  Recruiting Tanta University · Tanta, Gharbyea · NCT06961526

• Real-life experience with immunotherapy for liver cancer treatment

  This study is testing new combinations of immunotherapy treatments for liver cancer to see how well they work and how safe they are for patients.

  Recruiting at 16 sites IRCCS Azienda Ospedaliero-Universitaria di Bologna · Torrette, AN and 23 other locations · NCT06806579

• Combining radiotherapy and immunotherapy for advanced liver cancer before transplant

  This study is testing if combining radiation therapy with immunotherapy can help people with advanced liver cancer get better and qualify for a liver transplant.

  Recruiting Phase 1/2 University Health Network, Toronto · London, Ontario and 1 other locations · NCT06725121

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.